Altered Gut Microbiome under Antiretroviral Therapy: Impact of Efavirenz and Zidovudine.
Shilpa RayAswathy NarayananChristian G GiskeUjjwal NeogiAnders SönnerborgPiotr NowakPublished in: ACS infectious diseases (2020)
Millions of individuals currently living with HIV globally are receiving antiretroviral therapy (ART) that suppresses viral replication and improves host immune responses. The involvement of gut microbiome during HIV infection has been studied, exposing correlation with immune status and inflammation. However, the direct effect of ART on gut commensals of HIV-infected individuals has been mostly overlooked in microbiome studies. We used 16S rRNA sequencing (Illumina MiSeq) for determining the microbiota composition of stool samples from 16 viremic patients before and one year after ART. We also tested the direct effect of 15 antiretrovirals against four gut microbes, namely, Escherichia coli, Enterococcus faecalis, Bacteroides, and Prevotella to assess their in vitro antibacterial effect. 16S rRNA analysis of fecal samples showed that effective ART for one year does not restore the microbiome diversity in HIV-infected patients. A significant reduction in α-diversity was observed in patients under non-nucleoside reverse transcriptase inhibitors; (NNRTI; 2 NRTI+NNRTI; NRTIs are nucleoside reverse transcriptase inhibitors) as compared to ritonavir-boosted protease inhibitors (PI/r; 2 NRTI+PI/r). Prevotella (P = 0.00001) showed a significantly decreased abundance in patients after ART (n = 16). We also found the direct effect of antivirals on gut microbes, where zidovudine (ZDV) and efavirenz (EFV) showed in vitro antimicrobial activity against Bacteroides fragilis and Prevotella. EFV also inhibited the growth of E. faecalis. Therefore, we observed that ART does not reverse the HIV-induced gut microbiome dysbiosis and might aggravate those microbiota alterations due to the antibacterial effect of certain antiretrovirals (like EFV, ZDV). Our results imply that restructuring the microbiota could be a potential therapeutic target in HIV-1 patients under ART.
Keyphrases
- antiretroviral therapy
- hiv infected
- hiv infected patients
- human immunodeficiency virus
- hiv positive
- hiv aids
- end stage renal disease
- newly diagnosed
- escherichia coli
- chronic kidney disease
- ejection fraction
- prognostic factors
- peritoneal dialysis
- oxidative stress
- risk assessment
- hepatitis c virus
- patient reported outcomes
- sars cov
- pseudomonas aeruginosa
- south africa
- anaerobic digestion